CHECK OUT OUR
Press Releases
List of Services
-
Laverock Therapeutics to Present New Data on Programmable, Tunable, Stable and Specific Gene Silencing Platform at ESGCTContinue reading
Laverock Therapeutics today announces it is to present new data on its innovative gene-silencing platform at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome 22-25 October.
-
Laverock Therapeutics makes significant advances in its unique programmable gene silencing platform and announces pipeline focus on advanced therapies in oncology and genetic diseasesContinue reading
Laverock Therapeutics today announces significant progress in the industrialisation and validation of its technology platform enabling broadening of its potential therapeutic application.
-
Laverock Therapeutics announces forthcoming investor, scientific and partnering conference scheduleContinue reading
Laverock Therapeutics today announces its conference attendance programme for the remainder of 2024.
-
Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of teamContinue reading
Laverock Therapeutics announces the appointment of Ali Elsley as Finance Director. Laverock has also significantly grown its team to 24 people, representing growth of 50% over the past year.
-
Laverock raises £13.5mContinue reading
Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies
-
Laverock secures Innovate UK awardContinue reading List Item 1
Laverock Therapeutics secures Innovate UK award to advance immune effector cell therapeutics programme using GEiGS® technology
-
Laverock Therapeutics foundedContinue reading
Laverock Therapeutics founded to develop the next generation of programmable cell therapies
